American Century Companies Inc. Boosts Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

American Century Companies Inc. raised its position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 62.2% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,565 shares of the biopharmaceutical company’s stock after buying an additional 12,100 shares during the period. American Century Companies Inc. owned 0.12% of Inovio Pharmaceuticals worth $255,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Signature Estate & Investment Advisors LLC purchased a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at about $88,000. Rhumbline Advisers grew its position in shares of Inovio Pharmaceuticals by 5,943.0% during the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 37,857 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at approximately $661,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Inovio Pharmaceuticals during the 1st quarter valued at approximately $1,482,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Wall Street Analyst Weigh In

INO has been the subject of a number of research reports. Royal Bank of Canada reduced their target price on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating for the company in a research report on Friday. HC Wainwright reaffirmed a “neutral” rating and issued a $15.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, July 15th. Finally, Oppenheimer cut their price target on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating for the company in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $43.80.

Inovio Pharmaceuticals Stock Performance

Inovio Pharmaceuticals stock opened at $5.55 on Friday. The firm’s fifty day moving average price is $7.30 and its 200-day moving average price is $9.43. The stock has a market cap of $143.81 million, a P/E ratio of -1.51 and a beta of 0.82. Inovio Pharmaceuticals, Inc. has a fifty-two week low of $3.89 and a fifty-two week high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.09). The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.10 million. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 99.51%. During the same quarter last year, the business posted ($1.56) EPS. On average, analysts predict that Inovio Pharmaceuticals, Inc. will post -4.64 earnings per share for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.